Subgroup analyses comparing risk of immunogenicity [anti-drug antibodies formation] with anti-tumour necrosis factor-alpha drugs according to HLA-DQA1*05 carriage.
| Subgroup analysis . | Number of cohorts . | Risk ratio [95% confidence interval] . | I2 . | p-value . |
|---|---|---|---|---|
| Patient population | ||||
| Adult patients only | 3 | 2.17 [1.22 − 3.85] | 80% | 0.008 |
| Crohn’s disease patients only | 3 | 1.31 [0.98 − 1.74] | 67% | 0.06 |
| Type of TNFα antagonist | ||||
| Infliximab exclusively | 7 | 1.50 [1.10 − 2.05] | 77% | 0.01 |
| Adalimumab exclusively | 2 | 1.85 [1.18 − 2.90] | 39% | 0.008 |
| Publication type | ||||
| Abstracts | 4 | 1.81 [1.33 − 2.47] | 23% | <0.001 |
| Full papers | 6 | 1.42 [1.04 − 1.94] | 76% | 0.03 |
| Type of drug measurement assay | ||||
| Drug-tolerant assays | 5 | 1.28 [1.04 − 1.59] | 51% | 0.02 |
| Excluding high-risk bias studies | ||||
| Low/intermediate risk of bias | 6 | 1.41 [0.98 − 2.01] | 76% | 0.06 |
| Therapeutic drug monitoring | ||||
| Proactive | 4 | 1.24 [0.93 − 1.64] | 64% | 0.15 |
| No TDM strategy mentioned | 6 | 1.97 [1.35 − 2.88] | 66% | <0.001 |
| Subgroup analysis . | Number of cohorts . | Risk ratio [95% confidence interval] . | I2 . | p-value . |
|---|---|---|---|---|
| Patient population | ||||
| Adult patients only | 3 | 2.17 [1.22 − 3.85] | 80% | 0.008 |
| Crohn’s disease patients only | 3 | 1.31 [0.98 − 1.74] | 67% | 0.06 |
| Type of TNFα antagonist | ||||
| Infliximab exclusively | 7 | 1.50 [1.10 − 2.05] | 77% | 0.01 |
| Adalimumab exclusively | 2 | 1.85 [1.18 − 2.90] | 39% | 0.008 |
| Publication type | ||||
| Abstracts | 4 | 1.81 [1.33 − 2.47] | 23% | <0.001 |
| Full papers | 6 | 1.42 [1.04 − 1.94] | 76% | 0.03 |
| Type of drug measurement assay | ||||
| Drug-tolerant assays | 5 | 1.28 [1.04 − 1.59] | 51% | 0.02 |
| Excluding high-risk bias studies | ||||
| Low/intermediate risk of bias | 6 | 1.41 [0.98 − 2.01] | 76% | 0.06 |
| Therapeutic drug monitoring | ||||
| Proactive | 4 | 1.24 [0.93 − 1.64] | 64% | 0.15 |
| No TDM strategy mentioned | 6 | 1.97 [1.35 − 2.88] | 66% | <0.001 |
TDM, therapeutic drug monitoring; I2, statistical inconsistency.
Subgroup analyses comparing risk of immunogenicity [anti-drug antibodies formation] with anti-tumour necrosis factor-alpha drugs according to HLA-DQA1*05 carriage.
| Subgroup analysis . | Number of cohorts . | Risk ratio [95% confidence interval] . | I2 . | p-value . |
|---|---|---|---|---|
| Patient population | ||||
| Adult patients only | 3 | 2.17 [1.22 − 3.85] | 80% | 0.008 |
| Crohn’s disease patients only | 3 | 1.31 [0.98 − 1.74] | 67% | 0.06 |
| Type of TNFα antagonist | ||||
| Infliximab exclusively | 7 | 1.50 [1.10 − 2.05] | 77% | 0.01 |
| Adalimumab exclusively | 2 | 1.85 [1.18 − 2.90] | 39% | 0.008 |
| Publication type | ||||
| Abstracts | 4 | 1.81 [1.33 − 2.47] | 23% | <0.001 |
| Full papers | 6 | 1.42 [1.04 − 1.94] | 76% | 0.03 |
| Type of drug measurement assay | ||||
| Drug-tolerant assays | 5 | 1.28 [1.04 − 1.59] | 51% | 0.02 |
| Excluding high-risk bias studies | ||||
| Low/intermediate risk of bias | 6 | 1.41 [0.98 − 2.01] | 76% | 0.06 |
| Therapeutic drug monitoring | ||||
| Proactive | 4 | 1.24 [0.93 − 1.64] | 64% | 0.15 |
| No TDM strategy mentioned | 6 | 1.97 [1.35 − 2.88] | 66% | <0.001 |
| Subgroup analysis . | Number of cohorts . | Risk ratio [95% confidence interval] . | I2 . | p-value . |
|---|---|---|---|---|
| Patient population | ||||
| Adult patients only | 3 | 2.17 [1.22 − 3.85] | 80% | 0.008 |
| Crohn’s disease patients only | 3 | 1.31 [0.98 − 1.74] | 67% | 0.06 |
| Type of TNFα antagonist | ||||
| Infliximab exclusively | 7 | 1.50 [1.10 − 2.05] | 77% | 0.01 |
| Adalimumab exclusively | 2 | 1.85 [1.18 − 2.90] | 39% | 0.008 |
| Publication type | ||||
| Abstracts | 4 | 1.81 [1.33 − 2.47] | 23% | <0.001 |
| Full papers | 6 | 1.42 [1.04 − 1.94] | 76% | 0.03 |
| Type of drug measurement assay | ||||
| Drug-tolerant assays | 5 | 1.28 [1.04 − 1.59] | 51% | 0.02 |
| Excluding high-risk bias studies | ||||
| Low/intermediate risk of bias | 6 | 1.41 [0.98 − 2.01] | 76% | 0.06 |
| Therapeutic drug monitoring | ||||
| Proactive | 4 | 1.24 [0.93 − 1.64] | 64% | 0.15 |
| No TDM strategy mentioned | 6 | 1.97 [1.35 − 2.88] | 66% | <0.001 |
TDM, therapeutic drug monitoring; I2, statistical inconsistency.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
